These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24380613)

  • 21. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition.
    Connelly MA; Parry TJ; Giardino EC; Huang Z; Cheung WM; Chen C; Cools F; Van der Linde H; Gallacher DJ; Kuo GH; Sarich TC; Demarest KT; Damiano BP
    J Cardiovasc Pharmacol; 2010 May; 55(5):459-68. PubMed ID: 20051879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
    Vergeer M; Stroes ES
    Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
    J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
    Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
    Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
    Ferri N; Corsini A; Sirtori CR; Ruscica M
    Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on CETP inhibition.
    Davidson MH
    J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
    J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.